ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...

Treatment Pattern and Outcome of Locally Advanced Rectal Cancer in Resource-Constrained ... affect long-term patient outcomes in patients from Brazil diagnosed with prostate cancer is currently ...

Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including ...

Six months (vs. 3 years) of androgen suppression provided inferior survival for patients with locally advanced disease. Given emerging data about the potential harms of androgen-deprivation ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

Together, they addressed 19 critical questions related to prostate cancer management, including screening, biopsy techniques, handling localized and locally advanced disease, biochemical ...

Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

localised or locally advanced prostate cancer [ID6215] Technology appraisal guidance TBC Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172] Technology appraisal ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...